Please login to Zacks.com or register to post a comment.
| No Recent Quote currently available |
|
My Portfolio Tracker One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts. Set yours up today. |
Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.
Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.
Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.
My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.
| Company Name | Symbol | %Change |
|---|---|---|
| SCIENTIFIC L | SCIL | 8.00% |
| NATUS MEDICA | BABY | 6.11% |
| SUMMER INFAN | SUMR | 6.02% |
| RADIANT LOGI | RLGT | 5.32% |
| NEW ORIENTAL | EDU | 4.51% |
Please login to Zacks.com or register to post a comment.
Resources
Client Support
Zacks Research is Reported On:
Zacks Investment Research
is an A+ Rated BBB
Accredited Business.
Copyright 2013 Zacks Investment Research
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1986 it has nearly tripled the S&P 500 with an average gain of +26% per year. These returns cover a period from 1986-2011 and were examined and attested by Baker Tilly, an independent accounting firm.
Visit performance for information about the performance numbers displayed above.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This page is temporarily not available. Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext. 9339.
The beleaguered BlackBerry handset manufacturer Research In Motion Ltd. ( ) posted better than expected second quarter of fiscal 2013 financial results. Both the top and bottom line outpaced the Zacks Consensus Estimates. In the previous quarter, Research In Motion added net subscribers and its cash position improves sequentially. Management maintains its previous guideline that the BlackBerry 10 software-based smartphones will hit the market in the first calendar quarter of 2013.
The nightmare of Research In Motion continues ever since Apple Inc.’s ( AAPL - Analyst Report ) iPhone hit the market. The situation aggravated once Google Inc. ( GOOG - Analyst Report ) launched its Android software and several handset manufacturers adopted that operating system. Although we believe a real turnaround of Research In Motion will take more time than previously expected as we remain uncertain when the company will achieve profitability,the just concluded second-quarter of fiscal 2013 ushered some rays of hope as the market is eagerly waiting for the company’s next-generation Blackberry devices. We, thus, reaffirm our long-term Neutral recommendation on Research In Motion.
Research In Motion has initiated a headcount reduction in order to optimize its cost structure and has started benefiting from this restructuring process. The restructuring process will reduce its headcount by approximately 5,000 (about 30% of its present workforce) by the end of fiscal 2013. The headcount reduction will result into $1 billion of yearly cost savings. Furthermore, the Board of Directors has authorized a share buyback program of up to 5% of the company’s outstanding common shares. All these initiatives may improve the company’s bottom line going forward.
Read the full reports :
Analyst Report on GOOG
Analyst Report on AAPL